Holen Sie sich die Stockscreener-App
1.68
2.33%
-0.04
Handel nachbörslich:
1.67
-0.01
-0.60%
Schlusskurs vom Vortag:
$1.72
Offen:
$1.71
24-Stunden-Volumen:
668.29K
Relative Volume:
0.78
Marktkapitalisierung:
$162.44M
Einnahmen:
$69.56M
Nettoeinkommen (Verlust:
$-240.05M
KGV:
-0.5695
EPS:
-2.95
Netto-Cashflow:
$-121.90M
1W Leistung:
-5.08%
1M Leistung:
-15.58%
6M Leistung:
-49.40%
1J Leistung:
-46.15%
1-Tages-Spanne:
$1.64
$1.75
1-Wochen-Bereich:
$1.585
$1.82
52-Wochen-Spanne:
$1.585
$6.04
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Branche
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Vergleichen Sie ADCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.68 | 162.44M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Eingeleitet | Guggenheim | Buy |
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
ADC Therapeutics SA (NYSE:ADCT) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - BioSpace
ADC Therapeutics Takes Center Stage: Key Investor Presentation Coming at Major Biotech Conference - StockTitan
ADCT stock touches 52-week low at $1.66 amid market challenges - MSN
Brokers Set Expectations for ADCT FY2025 Earnings - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Expands By 18.0% - MarketBeat
Barclays PLC Raises Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA Reveals Preliminary ZYNLONTA Net Sales Information in Recent Corporate Presentation - Defense World
Institutional owners may consider drastic measures as ADC Therapeutics SA's (NYSE:ADCT) recent US$21m drop adds to long-term losses - Simply Wall St
Jane Street Group LLC Buys 38,859 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics : JP Morgan 43rd Annual Healthcare Conference - Marketscreener.com
Geode Capital Management LLC Buys 128,454 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates "Buy" Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
Barclays PLC Buys 93,890 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - IT News Online
Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value? - Yahoo Finance
ADC Therapeutics Grants Inducement Stock Options to New Employees in Retention Push | ADCT Stock News - StockTitan
ADC spikes after enrollment update on confirmatory trial for lymphoma therapy - MSN
ADC Therapeutics stock rises on enrollment update (ADCT:NYSE) - Seeking Alpha
ADC Therapeutics SA (NYSE:ADCT) Shares Purchased by State Street Corp - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Rises By 36.9% - MarketBeat
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma - PR Newswire
ADC Therapeutics Completes Enrollment in Pivotal ZYNLONTA Lymphoma Trial with 80% Response Rate - StockTitan
Fmr LLC Takes $167,000 Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Charles Schwab Investment Management Inc. Acquires 18,796 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Top 10 Companies to Watch Out for in Antibody Drug Conjugates - openPR
ADC Therapeutics' SWOT analysis: zynlonta sales challenges offset by expansion hopes - Investing.com
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development - Yahoo Finance UK
Redmile Group, Llc Acquires 100,000 Shares of ADC Therapeutics SA (NYSE:ADCT) Stock - MarketBeat
Research Analysts Issue Forecasts for ADCT FY2024 Earnings - Defense World
Redmile Group, LLC Increases Stake in ADC Therapeutics SA - GuruFocus.com
FY2024 Earnings Estimate for ADCT Issued By HC Wainwright - MarketBeat
Guggenheim Reaffirms “Buy” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
Adc therapeutics sees $609,000 in stock purchases by Redmile - Investing.com South Africa
ADC Therapeutics stock plunges 36% amid Zynlonta data release - MSN
HC Wainwright Reiterates “Buy” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics stock plunges 36% amid Zynlonta data release (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics shares drop after trial results By Investing.com - Investing.com South Africa
ADC Therapeutics shares drop after trial results - Investing.com
Adc Therapeutics Sa Announces Positive Initial Data from Lotis-7 Clinical Trial Evaluating Zynlonta®? in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Marketscreener.com
ADC Teeters on Trial Data - Baystreet.ca
ADC Therapeutics SA Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA®? in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Marketscreener.com
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Nasdaq
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma - Quantisnow
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial - Marketscreener.com
Adc Therapeutics Sa Announces the Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating Zynlonta®? in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma - Marketscreener.com
Insider Selling: ADC Therapeutics SA (NYSE:ADCT) Major Shareholder Sells 25,352 Shares of Stock - MarketBeat
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):